Impact of Trade Agreements on Access to HIV Medicines
Author Information
Author(s): Michael Westerhaus, Arachu Castro
Primary Institution: Harvard Medical School
Hypothesis
US-negotiated trade agreements hinder access to essential HIV medicines in poor countries.
Conclusion
The study concludes that current trade agreements and intellectual property laws significantly obstruct access to affordable antiretroviral therapy in low- and middle-income countries.
Supporting Evidence
- The TRIPS agreement has been criticized for limiting access to essential medicines in developing countries.
- Compulsory licenses for antiretroviral production have rarely been utilized.
- Health activists argue that patent laws lead to higher drug prices, obstructing access to treatment.
Takeaway
This study shows that rules about patents and trade make it hard for poor countries to get important medicines for HIV, which is really bad for people's health.
Methodology
The paper examines the relationship between intellectual property law and access to antiretroviral therapy through a review of trade agreements and their implications for public health.
Potential Biases
Potential bias may arise from the authors' affiliations with health advocacy organizations.
Limitations
The study does not provide empirical data on the direct impact of trade agreements on health outcomes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website